Shares in Regeneron (NSDQ:REGN) rose today after the company beat revenue expectations on The Street with its 1st quarter financial results.
The company’s total sales rose to $1.32 billion, exceeding analysts’ estimate of $1.30 billion. Regeneron’s bottom line jumped 37% to $248.9 million.
Get the full story at our sister site, Drug Delivery Business News.
The post Regeneron posts mixed Q1 results, Eylea growth slows appeared first on MassDevice.